14 Feb 2012
United Therapeutics Corporation Reports 2011 Fourth Quarter and Annual Financial Results
SILVER SPRING, Md., Feb. 14, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2011."I am pleased that we met our...
SILVER SPRING, Md., Feb. 7, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2011 financial results before market open on Tuesday...
SILVER SPRING, Md., Feb. 6, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. (Sandoz) advising...
SILVER SPRING, Md. and CHERTSEY, England, Dec. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and its wholly-owned subsidiary, United Therapeutics Europe, Ltd., announced today that the French...
SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011."We achieved over $200 million in...
SILVER SPRING, Md., Oct. 20, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2011 financial results before market open on Thursday, October 27...
SILVER SPRING, Md., Oct. 12, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced the pricing of its previously announced offering of $210 million aggregate principal amount...
SILVER SPRING, Md., Oct. 11, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced that it intends to offer, subject to market and other conditions, $210 million aggregate...
SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under...
24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an...
SILVER SPRING, Md., July 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2011."I'm pleased with the successful unblinding of...
SILVER SPRING, Md., July 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2011 financial results before market open on Thursday, July 28...